Alana M. Rojewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alana M. Rojewski has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin A. Toll
Department of Public Health Sciences, Medical University of South Carolina , 135 Cannon Street, Charleston, SC 29403
16 shared publications - Amanda M. Palmer
Department of Public Health Sciences, Medical University of South Carolina , Charleston, SC 29425
10 shared publications Benjamin A. Toll
Department of Public Health Sciences, Medical University of South Carolina; Division of Cancer Prevention and Control, Hollings Cancer Center, Medical University of South Carolina; Department of Psychiatry, Medical University of South Carolina
9 shared publications- Kinsey Pebley
Department of Population Health, University of Kansas Medical Center , 3901 Rainbow Blvd, Kansas City, KS 66160
5 shared publications - Matthew J. Carpenter
Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA
5 shared publications - Kenneth Michael Cummings
Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
Creating and testing the acceptability and feasibility of a novel video-based smoking cessation intervention tailored for individuals with cancer: results for alliance for clinical trials in oncology trial A21_Pilot 12
Introduction: Cigarette smoking poses unique risks for cancer survivors, but challenges remain with reach and efficacy of current interventions. The current randomized controlled pilot study created a video-based smoking cessation intervention for cancer survivors and tested acceptability/feasibility. Methods: Participants were cancer survivors ages 21+ reporting current smoking, could read/understand English, and did not have medical/psychiatric conditions impairing ability to consent. Three videos were created and shown to survivors (N = 10) and refined based on feedback. Four additional videos were then created. Participants (N = 40) were randomized to a video (n = 20, received 7 video links) or control (n = 20, received link to NCI’s “Clearing the Air” online booklet) group. Primary outcomes were acceptability/feasibility, assessed using the Acceptability and Feasibility of Intervention measures (scores ≥4 considered acceptable/feasible). Secondary outcomes included quit attempts, abstinence, cigarettes per day, and cessation resource use. Surveys were completed at baseline and 1-week, 1-month, and-3 months post-randomization. Results: Mean acceptability scores for video and control groups were 4.2 and 3.9, respectively. Mean feasibility scores for video and control groups were 4.0 and 3.8, respectively. Video participants saw decreases in cigarettes per day that were sustained from baseline (Mean [M] = 16.2) through final follow-ups (M = 7.7), and had numerically higher use of all nine cessation resources assessed. More video participants reported quit attempts at 1-week (55.0%), 1-month (50.0%), and 3-months (60.0%) than the control group (40.0% at 1-week and 1-month, 52.6% at 3-months). Conclusion: The video intervention was acceptable/feasible among a diverse sample. Larger studies assessing intervention efficacy are needed. Implications: The current study describes the creation of a novel video-based smoking cessation intervention tailored for cancer survivors (anyone who has received a cancer diagnosis) and subsequent acceptability and feasibility testing among a highly diverse sample. The video intervention was found to be acceptable and feasible among this vulnerable population, and promising trends related to smoking reductions and cessation resource use were identified.
- 6 October 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
Open AccessCreating and testing the acceptability and feasibility of a novel video-based smoking cessation intervention tailored for individuals with cancer: results for alliance for clinical trials in oncology trial A21_Pilot 12
Introduction: Cigarette smoking poses unique risks for cancer survivors, but challenges remain with reach and efficacy of current interventions. The current randomized controlled pilot study created a video-based smoking cessation intervention for cancer survivors and tested acceptability/feasibility. Methods: Participants were cancer survivors ages 21+ reporting current smoking, could read/understand English, and did not have medical/psychiatric conditions impairing ability to consent. Three videos were created and shown to survivors (N = 10) and refined based on feedback. Four additional videos were then created. Participants (N = 40) were randomized to a video (n = 20, received 7 video links) or control (n = 20, received link to NCI’s “Clearing the Air” online booklet) group. Primary outcomes were acceptability/feasibility, assessed using the Acceptability and Feasibility of Intervention measures (scores ≥4 considered acceptable/feasible). Secondary outcomes included quit attempts, abstinence, cigarettes per day, and cessation resource use. Surveys were completed at baseline and 1-week, 1-month, and-3 months post-randomization. Results: Mean acceptability scores for video and control groups were 4.2 and 3.9, respectively. Mean feasibility scores for video and control groups were 4.0 and 3.8, respectively. Video participants saw decreases in cigarettes per day that were sustained from baseline (Mean [M] = 16.2) through final follow-ups (M = 7.7), and had numerically higher use of all nine cessation resources assessed. More video participants reported quit attempts at 1-week (55.0%), 1-month (50.0%), and 3-months (60.0%) than the control group (40.0% at 1-week and 1-month, 52.6% at 3-months). Conclusion: The video intervention was acceptable/feasible among a diverse sample. Larger studies assessing intervention efficacy are needed. Implications: The current study describes the creation of a novel video-based smoking cessation intervention tailored for cancer survivors (anyone who has received a cancer diagnosis) and subsequent acceptability and feasibility testing among a highly diverse sample. The video intervention was found to be acceptable and feasible among this vulnerable population, and promising trends related to smoking reductions and cessation resource use were identified.
- Open Access
- 29 June 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 28  (11) , 1961-1966
Tobacco use and cessation strategies among individuals recently diagnosed with cancer
Introduction: Smoking cessation following a cancer diagnosis is critical for improving prognosis. For this reason, substantial efforts have been made to increase tobacco treatment in cancer care settings. The purpose of the present study is to provide an up-to-date estimate of tobacco/nicotine product use (inclusive of non-combustible products such as e-cigarettes and oral nicotine pouches) and cessation strategy uptake among individuals recently diagnosed with cancer. Methods: Data were derived from the Population Assessment of Tobacco and Health study, a large, nationally representative survey. Weighted frequencies estimated tobacco/nicotine product use (eg, cigarettes, cigars, e-cigarettes, oral pouches) and cessation strategy prevalence (eg, nicotine replacement therapies, prescription medications, e-cigarettes, oral pouches). Logistic regressions evaluated the associations between cancer diagnosis and cancer type (eg, tobacco related vs non-tobacco related cancers) on tobacco use and cessation strategy outcomes. Results: Individuals with cancer used tobacco/nicotine products at similar rates as those without cancer. Individuals with cancer were more likely to use evidence-based cessation strategies (eg, pharmacotherapy and counseling; Adjusted odds ratio [AOR] = 2.36 [95% CI, 1.30-4.27], P < .01), but appeared less likely to successfully quit (17.27% [5.42–29.13]) with cancer quit vs 31.16% [28.39–33.93] without cancer). Similarly, those with tobacco-related cancers appeared to have higher engagement with cessation strategies (11.90% [5.95–17.84]) than those with non-tobacco-related cancers (2.35% [0.74–3.95]). Conclusions: Efforts to increase reach and access to evidence-based cessation support in cancer settings have been fruitful; however, more work is needed to improve treatment effectiveness. Continued monitoring of the use of non-combustible products is warranted. Implications: Little is known about the contemporary prevalence of tobacco/nicotine product use and uptake of evidence-based and product substitution cessation strategies among individuals with cancer relative to those without cancer. Although they did not differ from non-cancer counterparts in terms of nicotine/tobacco use, individuals with cancer were more likely to use evidence-based cessation strategies, but appeared less likely to successfully quit. Non-cigarette product use was not a common smoking cessation strategy. Individuals with cancer are likely to seek evidence-based tobacco cessation support, but effectiveness could be improved.
- 29 June 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 28  (11) , 1961-1966
Open AccessTobacco use and cessation strategies among individuals recently diagnosed with cancer
Introduction: Smoking cessation following a cancer diagnosis is critical for improving prognosis. For this reason, substantial efforts have been made to increase tobacco treatment in cancer care settings. The purpose of the present study is to provide an up-to-date estimate of tobacco/nicotine product use (inclusive of non-combustible products such as e-cigarettes and oral nicotine pouches) and cessation strategy uptake among individuals recently diagnosed with cancer. Methods: Data were derived from the Population Assessment of Tobacco and Health study, a large, nationally representative survey. Weighted frequencies estimated tobacco/nicotine product use (eg, cigarettes, cigars, e-cigarettes, oral pouches) and cessation strategy prevalence (eg, nicotine replacement therapies, prescription medications, e-cigarettes, oral pouches). Logistic regressions evaluated the associations between cancer diagnosis and cancer type (eg, tobacco related vs non-tobacco related cancers) on tobacco use and cessation strategy outcomes. Results: Individuals with cancer used tobacco/nicotine products at similar rates as those without cancer. Individuals with cancer were more likely to use evidence-based cessation strategies (eg, pharmacotherapy and counseling; Adjusted odds ratio [AOR] = 2.36 [95% CI, 1.30-4.27], P < .01), but appeared less likely to successfully quit (17.27% [5.42–29.13]) with cancer quit vs 31.16% [28.39–33.93] without cancer). Similarly, those with tobacco-related cancers appeared to have higher engagement with cessation strategies (11.90% [5.95–17.84]) than those with non-tobacco-related cancers (2.35% [0.74–3.95]). Conclusions: Efforts to increase reach and access to evidence-based cessation support in cancer settings have been fruitful; however, more work is needed to improve treatment effectiveness. Continued monitoring of the use of non-combustible products is warranted. Implications: Little is known about the contemporary prevalence of tobacco/nicotine product use and uptake of evidence-based and product substitution cessation strategies among individuals with cancer relative to those without cancer. Although they did not differ from non-cancer counterparts in terms of nicotine/tobacco use, individuals with cancer were more likely to use evidence-based cessation strategies, but appeared less likely to successfully quit. Non-cigarette product use was not a common smoking cessation strategy. Individuals with cancer are likely to seek evidence-based tobacco cessation support, but effectiveness could be improved.
- 24 April 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212  (6) , 1170-1173
Nicotine replacement therapy starter packs and gain-framed messages to promote smoking cessation in lung cancer screening: a randomized trial
- 24 April 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212  (6) , 1170-1173
Nicotine replacement therapy starter packs and gain-framed messages to promote smoking cessation in lung cancer screening: a randomized trial
- Open Access
- 20 April 2026
- Published by Elsevier in Preventive Medicine Reports
- Vol. 66, 103480
Lung cancer screening outcomes among people with HIV at an academic medical center in South Carolina: insights from electronic health records and provider survey data 2023
- 20 April 2026
- Published by Elsevier in Preventive Medicine Reports
- Vol. 66, 103480
Open AccessLung cancer screening outcomes among people with HIV at an academic medical center in South Carolina: insights from electronic health records and provider survey data 2023
- Open Access
- 23 October 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9  (1) , e76792
Thematic Analysis of Smoking Cessation and Future Cessation Interventions for Cancer Survivors: Convenience Sampling Study
Background: Smoking after a cancer diagnosis has significant health consequences, and there are substantial benefits if cancer survivors cease smoking. However, there are few smoking cessation interventions for cancer survivors that have been effective, and they are highly resource intensive. Thus, novel low resource cessation interventions are needed. One such intervention modality that has not been tested among cancer survivors is using pre-recorded videos to deliver information about skills and resources to achieve smoking cessation. Objective: This study aimed to assess barriers to smoking cessation, interest in a video-based smoking cessation intervention, and video content preferences (eg, topic, video length, age and gender of video presenter, presenter type [peer, medical professional]) among individuals with cancer who smoke cigarettes. Methods: Participants were recruited from a cancer center in the southeast United States that houses an opt-out tobacco treatment program in which tobacco treatment specialists proactively call all patients who have a current smoking status in their medical record. Patients were informed about the study, and their contact information was sent to the study team. Verbal consent was obtained from individuals who were cancer survivors, who were currently smoking, and who agreed to participate; semi-structured qualitative interviews were conducted (n=10). Participants were asked questions about smoking history, previous quit attempts, barriers to quitting smoking, previous experience with and openness to watching videos about quitting smoking, and participant preferences related to video content and presentation. Interviews were transcribed and coded by two reviewers, and a codebook was developed. A thematic analysis was then conducted. Results: Results indicated that all participants had previously tried to quit smoking, but other substance use (5/10; 50%), negative affect (eg, depression [4/10; 40%], anxiety [1/10; 10%], stress [2/10; 20%], and loneliness [1/10; 10%]), the social environment (eg, being around others who smoke [2/10; 20%] and risky social situations [2/10; 20%]), and habits surrounding smoking were significant barriers for cessation. All participants were open to watching smoking cessation videos and expressed a desire to see a peer with lived experience in the videos. Most (8/10; 80%) participants did not have preferences related to the age or gender of video presenters. Many participants had difficulty articulating content preferences for the videos. Conclusions: Cancer survivors who smoke may not be aware of their knowledge gaps related to smoking cessation, and videos may be an acceptable way to provide evidence-based information to fill knowledge gaps.
- 23 October 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9  (1) , e76792
Open AccessThematic Analysis of Smoking Cessation and Future Cessation Interventions for Cancer Survivors: Convenience Sampling Study
Background: Smoking after a cancer diagnosis has significant health consequences, and there are substantial benefits if cancer survivors cease smoking. However, there are few smoking cessation interventions for cancer survivors that have been effective, and they are highly resource intensive. Thus, novel low resource cessation interventions are needed. One such intervention modality that has not been tested among cancer survivors is using pre-recorded videos to deliver information about skills and resources to achieve smoking cessation. Objective: This study aimed to assess barriers to smoking cessation, interest in a video-based smoking cessation intervention, and video content preferences (eg, topic, video length, age and gender of video presenter, presenter type [peer, medical professional]) among individuals with cancer who smoke cigarettes. Methods: Participants were recruited from a cancer center in the southeast United States that houses an opt-out tobacco treatment program in which tobacco treatment specialists proactively call all patients who have a current smoking status in their medical record. Patients were informed about the study, and their contact information was sent to the study team. Verbal consent was obtained from individuals who were cancer survivors, who were currently smoking, and who agreed to participate; semi-structured qualitative interviews were conducted (n=10). Participants were asked questions about smoking history, previous quit attempts, barriers to quitting smoking, previous experience with and openness to watching videos about quitting smoking, and participant preferences related to video content and presentation. Interviews were transcribed and coded by two reviewers, and a codebook was developed. A thematic analysis was then conducted. Results: Results indicated that all participants had previously tried to quit smoking, but other substance use (5/10; 50%), negative affect (eg, depression [4/10; 40%], anxiety [1/10; 10%], stress [2/10; 20%], and loneliness [1/10; 10%]), the social environment (eg, being around others who smoke [2/10; 20%] and risky social situations [2/10; 20%]), and habits surrounding smoking were significant barriers for cessation. All participants were open to watching smoking cessation videos and expressed a desire to see a peer with lived experience in the videos. Most (8/10; 80%) participants did not have preferences related to the age or gender of video presenters. Many participants had difficulty articulating content preferences for the videos. Conclusions: Cancer survivors who smoke may not be aware of their knowledge gaps related to smoking cessation, and videos may be an acceptable way to provide evidence-based information to fill knowledge gaps.
- 21 May 2025
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 69  (2) , 107664
Augmented Doses of Nicotine Replacement Therapy: Feasibility for Dual Cigarette and E-Cigarette Cessation
- 21 May 2025
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 69  (2) , 107664
Augmented Doses of Nicotine Replacement Therapy: Feasibility for Dual Cigarette and E-Cigarette Cessation
- Open Access
- 2 April 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22  (4) , 543
Gain-Framed Text Messages and Nicotine Replacement Therapy for Smoking Cessation Among Lung Cancer Screening Patients: A Brief Report of a Pilot Randomized Controlled Trial
People who undergo lung cancer screening (LCS) and continue to smoke are at risk for negative clinical outcomes and lowered survival and need effective smoking cessation interventions. This pilot study tested an 8-week intervention for smoking cessation after LCS. The participants (N = 40) were randomized to the intervention group (combination nicotine replacement therapy [NRT] plus gain-framed text messaging for 8 weeks) or the control group (standard cessation counseling) after LCS. Assessments were completed at 8-week and 3-month follow-ups, including self-reported 7-day point prevalence abstinence. The mean age was 64.4 years old (SD = 6.2); 32.5% were Black or African American; and 55% were female. At Week 8, 14.3% (3/21) of the participants in the intervention group were abstinent versus 0% (0/19) in the control group (p > 0.05). At 3-month follow-up, 4.8% (1/21) of the participants in the intervention group were abstinent versus 0% (0/19) in the control group. Among the intervention group participants, up to 52.4% used the provided patches and up to 61.9% used the provided lozenges during the study period. This study demonstrated modest quit rates for LCS patients receiving gain-framed text messages and NRT. The results highlight the need for more effective smoking cessation interventions for this priority population.
- 2 April 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22  (4) , 543
Open AccessGain-Framed Text Messages and Nicotine Replacement Therapy for Smoking Cessation Among Lung Cancer Screening Patients: A Brief Report of a Pilot Randomized Controlled Trial
People who undergo lung cancer screening (LCS) and continue to smoke are at risk for negative clinical outcomes and lowered survival and need effective smoking cessation interventions. This pilot study tested an 8-week intervention for smoking cessation after LCS. The participants (N = 40) were randomized to the intervention group (combination nicotine replacement therapy [NRT] plus gain-framed text messaging for 8 weeks) or the control group (standard cessation counseling) after LCS. Assessments were completed at 8-week and 3-month follow-ups, including self-reported 7-day point prevalence abstinence. The mean age was 64.4 years old (SD = 6.2); 32.5% were Black or African American; and 55% were female. At Week 8, 14.3% (3/21) of the participants in the intervention group were abstinent versus 0% (0/19) in the control group (p > 0.05). At 3-month follow-up, 4.8% (1/21) of the participants in the intervention group were abstinent versus 0% (0/19) in the control group. Among the intervention group participants, up to 52.4% used the provided patches and up to 61.9% used the provided lozenges during the study period. This study demonstrated modest quit rates for LCS patients receiving gain-framed text messages and NRT. The results highlight the need for more effective smoking cessation interventions for this priority population.
- Open Access
- 22 March 2025
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27  (10) , 1739-1749
Tobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials
Introduction: Tobacco use can adversely affect cancer treatment outcomes, yet routine assessment has not been fully incorporated into oncology clinical trials. In 2012, rates of tobacco use assessment in actively accruing National Cancer Institute (NCI) trials were < 30% at enrollment and < 5% during follow-up, prompting efforts by the NCI and major oncology associations to promote and standardize tobacco assessment in oncology research and practice (including development of the Cancer Patient Tobacco Use Questionnaire [C-TUQ]). This study was conducted to re-examine assessment patterns in 2022 (including utilization of the C-TUQ) and evaluate progress. Aims and Methods: Protocols and forms from 144 actively accruing (as of December 2022) NCI National Clinical Trials Network (NCTN) trials were evaluated using a standardized coding instrument. Results: Of 144 trials, 49.3% assessed tobacco use at enrollment (43.8% measured cigarettes, 14.8% e-cigarettes, and ≤ 12.5% other tobacco products). Approximately 20.8% used at least one C-TUQ question, but only 3.5% used all four core items. Few measured second-hand smoke exposure (3.5%) or quit interest (2.8%). At follow-up, 8.3% assessed any form of tobacco use. Assessment rates were higher in smoking-related cancer trials. Conclusions: Almost half of the accruing trials did not measure any tobacco use and fewer used the C-TUQ. There was a ≥ 70% increase in tobacco use assessment at enrollment and follow-up compared to 2012, an improvement with room for further enhancement. Standardized tobacco use information enhances investigators’ ability to estimate cancer treatment efficacy, offer equitable cessation support, and accurately understand the impact of tobacco use on treatment outcomes. Implications: In 2012, few (< 30%) cancer clinical trials evaluated tobacco use at enrollment and < 5% did so during follow-up, prompting efforts to promote and standardize tobacco assessment in oncology research and practice (including the development of the Cancer Patient Tobacco Use Questionnaire [C-TUQ]). The present study builds on this foundational paper and finds an overall increase in tobacco use assessment with room for improvement: 49.3% of trials in 2022 assessed tobacco use at enrollment and 8.3% did so during follow-up. About 20.8% used at least one C-TUQ question, highlighting that tobacco use assessment is not yet fully incorporated into oncology clinical trials.
- 22 March 2025
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27  (10) , 1739-1749
Open AccessTobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials
Introduction: Tobacco use can adversely affect cancer treatment outcomes, yet routine assessment has not been fully incorporated into oncology clinical trials. In 2012, rates of tobacco use assessment in actively accruing National Cancer Institute (NCI) trials were < 30% at enrollment and < 5% during follow-up, prompting efforts by the NCI and major oncology associations to promote and standardize tobacco assessment in oncology research and practice (including development of the Cancer Patient Tobacco Use Questionnaire [C-TUQ]). This study was conducted to re-examine assessment patterns in 2022 (including utilization of the C-TUQ) and evaluate progress. Aims and Methods: Protocols and forms from 144 actively accruing (as of December 2022) NCI National Clinical Trials Network (NCTN) trials were evaluated using a standardized coding instrument. Results: Of 144 trials, 49.3% assessed tobacco use at enrollment (43.8% measured cigarettes, 14.8% e-cigarettes, and ≤ 12.5% other tobacco products). Approximately 20.8% used at least one C-TUQ question, but only 3.5% used all four core items. Few measured second-hand smoke exposure (3.5%) or quit interest (2.8%). At follow-up, 8.3% assessed any form of tobacco use. Assessment rates were higher in smoking-related cancer trials. Conclusions: Almost half of the accruing trials did not measure any tobacco use and fewer used the C-TUQ. There was a ≥ 70% increase in tobacco use assessment at enrollment and follow-up compared to 2012, an improvement with room for further enhancement. Standardized tobacco use information enhances investigators’ ability to estimate cancer treatment efficacy, offer equitable cessation support, and accurately understand the impact of tobacco use on treatment outcomes. Implications: In 2012, few (< 30%) cancer clinical trials evaluated tobacco use at enrollment and < 5% did so during follow-up, prompting efforts to promote and standardize tobacco assessment in oncology research and practice (including the development of the Cancer Patient Tobacco Use Questionnaire [C-TUQ]). The present study builds on this foundational paper and finds an overall increase in tobacco use assessment with room for improvement: 49.3% of trials in 2022 assessed tobacco use at enrollment and 8.3% did so during follow-up. About 20.8% used at least one C-TUQ question, highlighting that tobacco use assessment is not yet fully incorporated into oncology clinical trials.